SOHM Inc (OTCMKTS:SHMN) Stock Gains Momentum: How To Trade It Now?

The generic pharmaceutical manufacturing space has always attracted a considerable degree of attention from investors and investors are almost always on the lookout for such companies. One of the companies which they could look into right now is SOHM Inc (OTCMKTS:SHMN), which is an emerging generic pharmaceutical manufacturing and marketing firm with the vision of ‘Global Prospero’.

The company has aimed to grow continuously. The manufacturing and market segments that the company targets had evolved at a rapid pace. It is now involved in segments like cosmeceuticals, nutraceuticals, and other therapeutic spaces. The SOHM stock was in prime focus on Tuesday and had managed to clock gains of as much as 22% amidst significant focus. It could be a good idea now for investors to consider taking a closer look at the company and make their minds up about the stock.

The rally in the stock came about on Tuesday after the company announced that it had inked a letter of intent with regards to the acquisition of ABBE, a stem cell distributive technology and patents. Dr. David Aguilar, who is the owner of the technology along with the patents with his partners, presented the letter of intent to SOHM. The proposal was for SOHM to acquire CGA Intellectual Holdings Inc and its patented technology.

Through this acquisition, it would be possible to use the state-of-the-art disruptive life sciences and stem cell regenerative technology to create unique solutions in the cosmeceutical and regenerative medicine spaces. The patents for the technology had already been awarded in China and are currently pending in the European Union, Japan, the United States, and South Korea.

Additionally, Dr. Aguilar also noted that the CRISPR/CAS systems which are offered by CAG would also be a major factor in accelerating genome editing and making it more accessible to a larger number of laboratories.

The new generation of genome testing not only provides higher efficiency of recombination but also boosts targetability. Dr. Aguilar went on to note that the system could also be used as a ‘plug and play’ system through the generation of alternative donor DNA.

Last week the company announced that it had managed to close the financing-funding related to many of its currently ongoing and future projects. Baron Night, the Chief Executive Officer of SOHM, noted that the company managed to secure the requisite funding for the San Diego pharmaceutical facility, which would have both Phase 1 and Phase 2.

He went on to note that any funds which may be in excess of requirements would be invested in future projects that may take SOHM to new levels. It was announced that SOHM had managed to secure as much as $5.5 million in financing and already receive the first installment by way of a financial note. The night also revealed that the company would receive the funding in tranches over the course of a year as it continued to complete the different projects. The majority of the funds are from Preferred A Shares, while the rest are from financial notes.